bosutinib (Bosulif, SKI-606)
Jump to navigation
Jump to search
Indications
- Philadelphia chromosome positive chronic myelogenous leukemia (CML)
- not recommended (NICE), see NGC guideline
- autosomal dominant polycystic kidney disease (ADPKD)[4]
- may slow cyst growth (66%)
Dosage
Tabs: 100 mg, 500 mg
Adverse effects
- common (> 20%)
- diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue
- serious adverse reactions
- anaphylactic shock, myelosuppression, hepatoxicity
Mechanism of action
More general terms
References
- ↑ Wikipedia: Bosutinib http://en.wikipedia.org/wiki/Bosutinib
- ↑ FDA Approval for Bosutinib, September 4, 2012 National Cancer Institute http://www.cancer.gov/cancertopics/druginfo/fda-bosutinib
- ↑ Cortes JE et al Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. J Clin Oncol. 2012 Oct 1;30(28):3486-92. Epub 2012 Sep 4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22949154
- ↑ 4.0 4.1 Minerd J Cancer Drug May Help in ADPKD. Bosutinib slowed kidney enlargement in phase II study. MedPage Today. August 24, 2017 https://www.medpagetoday.com/Nephrology/GeneralNephrology/67482
Tesar V, Ciechanowski K, Pei Y al Bosutinib versus placebo for autosomal dominant polycystic kidney disease J Am Soc Nephrol. 2017 Aug 24. pii: ASN.2016111232. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28838955